MedTrace Logo

Brain Energy and Aging With Triheptanoin

NCT02679235 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-07-23

Study results available
· View outcomes & findings →

Summary

BEAT7-001 is a single group study (supplementation). Using a multi-modal brain imaging portfolio, this study will assess whether brain energy metabolism (glucose and ketones), structure or functional connectivity change in older people with frontal glucose hypometabolism after 28 days on an oral dose of 1 g/kg/day of triheptanoin.

Conditions

  • Frontal Lobe Hypometabolism

Interventions

DRUG

POST Triheptanoin

The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.

Sponsors & Collaborators

  • Ultragenyx Pharmaceutical Inc

    collaborator INDUSTRY

  • Fonds de la Recherche en Santé du Québec

    collaborator OTHER_GOV

  • Université de Sherbrooke

    lead OTHER

Principal Investigators

  • Stephen Cunnane, Ph.D. · Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-08-08
Completion
2018-08-08

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02679235 on ClinicalTrials.gov